|
I like IMNR better than HIV. IMNR also released data on an AIDS prophylactic vaccine a few months back. The problem is that IMNR's and HIV's prophylactic vaccine studies are done with mice and are 7 years away from any meaningful drug, if at all. IMNR is a better investment than cell-sci because of the many different drugs in their pipeline. They have a therapeutic aids vaccine, called REMUNE, which is in a 2500 patient phase 3 study, as well as Rheumatoid Arthritis, Psoriasis, Gene Thereapy, Multiple Sclerosis, Cancer, etc. drugs in their pipeline. If you choose to invest in the risky biotech field, look for companies that have more than 1 product. IMNR had more great news on their Aids drug today, and shareholders expect eventual approval of REMUNE in 1999 by the FDA. When it does get approved, the stock should trade in the 60 dollar range, at a minimum, but perhaps over 100 dollars (see Agouron as a comparison--went to 110 before it split). |
